Spots Global Cancer Trial Database for tumor recurrence
Every month we try and update this database with for tumor recurrence cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma | NCT04499833 | Hepatocellular ... Recurrence Tumo... | liver transplan... | 18 Years - 70 Years | Centro Hospitalar de Lisboa Central | |
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | NCT01340729 | Metastatic Mela... | TPI 287 | 15 Years - | M.D. Anderson Cancer Center | |
FDG and FDOPA PET Demonstration of Functional Brain Abnormalities | NCT04315584 | Glioblastoma | Positron Emissi... Computed Tomogr... Multiparametric... Fludeoxyglucose... fluorine F 18 f... | 18 Years - | University of Virginia | |
HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma | NCT04499833 | Hepatocellular ... Recurrence Tumo... | liver transplan... | 18 Years - 70 Years | Centro Hospitalar de Lisboa Central | |
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | NCT01340729 | Metastatic Mela... | TPI 287 | 15 Years - | M.D. Anderson Cancer Center | |
Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies | NCT05457595 | Tumor Recurrenc... Malignant Epith... Malignant Epith... Malignant Epith... | carbon ion radi... | 18 Years - | CNAO National Center of Oncological Hadrontherapy | |
Outcome Analysis of Aspirin in Liver Transplantation | NCT04327427 | Liver Transplan... | Aspirin | 18 Years - | University of Zurich | |
HOPE to Reduce Tumour Recurrence After LT In Patients With HCC | NCT05876052 | Liver Cancer Tumor Recurrenc... Hepatocellular ... Liver Transplan... Ex-vivo Hypothe... | Hypothermic oxy... | 18 Years - | University of Bologna | |
Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma | NCT03515369 | Hepatocellular ... Tumor Recurrenc... | Babaodan oral c... Placebo oral ca... | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer | NCT05704231 | Non-Muscle Inva... Self Efficacy Smoking Behavio... Tumor Recurrenc... Progression, Di... | Behavioral: Mot... | 21 Years - | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | |
Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies | NCT05457595 | Tumor Recurrenc... Malignant Epith... Malignant Epith... Malignant Epith... | carbon ion radi... | 18 Years - | CNAO National Center of Oncological Hadrontherapy | |
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | NCT03383094 | Head and Neck S... Cancer Cancer of Head ... Cancer, Advance... Cancer, Metasta... Tumor Tumor Recurrenc... Tumor Neck Tumor Metastasi... Oral Cancer Oropharyngeal C... Oropharynx Canc... Oropharynx Canc... Oropharynx Canc... Oropharynx Canc... | Pembrolizumab Radiation thera... Cisplatin | 18 Years - | University of California, San Diego | |
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) | NCT01172548 | Gastrointestina... | imatinib mesyla... | 18 Years - | Novartis | |
Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis | NCT05095766 | Brain Metastase... | 18 Years - | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | ||
Markers of Response to Intravesical Bladder Cancer Therapy | NCT01007058 | Bladder Cancer | 18 Years - | M.D. Anderson Cancer Center |